Caribou Biosciences (CRBU) vs INmune Bio (INMB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
INmune Bio (INMB) has outperformed Caribou Biosciences (CRBU) over the past year, losing 9.0% versus a loss of 82.0%. Over five years, INMB leads with a -90.2% price change compared with -97.7% for CRBU. Caribou Biosciences is the larger company by market cap ($51.6 million vs $50.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBU | INMB |
|---|---|---|
| Share price | $0.4812 | $1.83 |
| Market cap | $51.59M | $50.79M |
| 1-day change | -22.06% | -1.61% |
| YTD return | -69.74% | +17.31% |
| 1-year return | -82.04% | -8.96% |
| 5-year return | -97.69% | -90.17% |
| EPS (TTM) | $-1.08 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.54 | $2.60 |
| 52-week low | $0.45 | $1.09 |
| Distance from 52-week high | -86.39% | -29.62% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +1094.93% | +282.51% |
| Average volume | 2.14M | 402.12K |
| Shares outstanding | 107.21M | 27.75M |
| Employees | 97 | 21 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INMB has outperformed CRBU by 73.1 percentage points over the past year.
About Caribou Biosciences
CRBU stock →Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company.
Healthcare · Biotechnology · 97 employees
About INmune Bio
INMB stock →INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Healthcare · Biotechnology · 21 employees
CRBU vs INMB FAQ
Which is bigger, Caribou Biosciences or INmune Bio?
Caribou Biosciences (CRBU) is larger, with a market capitalization of $51.59M compared with $50.79M for INmune Bio (INMB).
Which stock has performed better over the past year, CRBU or INMB?
INMB returned -8.96% over the past 12 months, compared with -82.04% for CRBU (price return, excluding dividends). Past performance does not predict future results.
Are Caribou Biosciences and INmune Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.